Protocol 1 from Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2− Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial
Authors:
- Séverine GuiuSGSéverine Guiu
- Judith BalmañaJBJudith Balmaña
- Pablo LemercierPLPablo Lemercier
- Philippe FollanaPFPhilippe Follana
- Anthony GonçalvesAnthony Gonçalves
- Frédéric BigotFBFrédéric Bigot
- Jean-Sébastien FrenelJFJean-Sébastien Frenel
- Etienne BrainEBEtienne Brain
- Audrey MailliezAMAudrey Mailliez
- Camille Chakiba BrugereCBCamille Chakiba Brugere
- Elsa CurtitECElsa Curtit
- Olfa DerbelODOlfa Derbel
Open Access
- 14 November 2025
- other
- Published by American Association for Cancer Research (AACR)
Abstract
EudraCT n°: 2018-003832-57 DOLAF-An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.Keywords
This publication has 56 references indexed in Scilit:
- Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancerCancer Treatment Reviews, 2018
- Men and women show similar survival outcome in stage IV breast cancerThe Breast, 2017
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialThe Lancet, 2016
- Enlisting the Immune System to Cure Breast Cancer—A Recipe for SuccessJAMA Oncology, 2016
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancerBiochemical and Biophysical Research Communications, 2015
- Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence dataBreast Cancer Research and Treatment, 2014
- PTEN C-Terminal Deletion Causes Genomic Instability and Tumor DevelopmentCell Reports, 2014
- Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunityAutoimmunity Reviews, 2013
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An updateInternational Journal of Cancer, 2005